Richette, Pascal
Perez-Ruiz, Fernando
Doherty, Michael
Jansen, Tim L.
Nuki, George
Pascual, Eliseo
Punzi, Leonardo
So, Alexander K.
Bardin, Thomas
Article History
First Online: 19 August 2014
Competing interests
: The authors declare they have received consultancy and/or speaker fees from Abbott (T.L.J.), Ardea Biosciences (F.P.-R., M.D., G.N., A.K.S., T.B.), Astra Zeneca (P.R.), Biocryst (G.N., T.B.), Ipsen (P.R., M.D., T.L.J., G.N., A.K.S., T.B.), Menarini (P.R., F.P.-R., M.D., T.L.J., G.N., E.P., A.K.S., T.B.), Metabolex (F.P.-R.), Novartis (P.R., F.P.-R., M.D., G.N., A.K.S., T.B.), Pfizer (F.P.-R.), Roche (T.L.J.), Sanofi (P.R.), Savient (P.R., F.P.-R. G.N., M.D., E.P., T.B.) and UCB (T.L.J.). F.P.-R. declares he has received grants from Ministerio de Sanidad, Gobierno de España and Asociación de Reumatólogos del Hospital de Cruces. P.R. declares he has received an educational grant from Menarini.